Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

David Ellenberger, Kerstin Eichstädt,Peter Flachenecker,Tim Friede,Judith Haas,Christoph Kleinschnitz,Dieter Pöhlau,Otto Rienhoff,Alexander Stahmann,Uwe K Zettl,Paulus S Rommer

Multiple Sclerosis and Related Disorders（2018）

引用 8|浏览14

暂无评分

摘要

•Glucocorticosteroid (GCS) continuous to decrease in Germany.•Natalizumab utilization decreased with the emergence of additional treatment options.•GCS utilization decreases for both RRMS and SPMS.•The generally observed decrease in relapses per year is confirmed with in the data.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要